[go: up one dir, main page]

WO2008073316A3 - Identification et isolation de cellules souches de leucémie myéloïde aiguë - Google Patents

Identification et isolation de cellules souches de leucémie myéloïde aiguë Download PDF

Info

Publication number
WO2008073316A3
WO2008073316A3 PCT/US2007/025113 US2007025113W WO2008073316A3 WO 2008073316 A3 WO2008073316 A3 WO 2008073316A3 US 2007025113 W US2007025113 W US 2007025113W WO 2008073316 A3 WO2008073316 A3 WO 2008073316A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
myeloid leukemia
acute myeloid
isolation
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/025113
Other languages
English (en)
Other versions
WO2008073316A2 (fr
Inventor
Irving L Weissman
Naoki Hosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to EP07862659.5A priority Critical patent/EP2097535B1/fr
Publication of WO2008073316A2 publication Critical patent/WO2008073316A2/fr
Publication of WO2008073316A3 publication Critical patent/WO2008073316A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'identification de cellules souches de leucémie myéloïde aiguë (AMLSC). Les cellules peuvent être prospectivement isolées et identifiées à partir d'échantillons prélevés sur un patient, et possèdent les caractéristiques uniques des cellules souches du cancer dans des essais fonctionnels pour l'auto-régénérescence et la différentiation de cellules souches, et dans le diagnostic du cancer.
PCT/US2007/025113 2006-12-07 2007-12-07 Identification et isolation de cellules souches de leucémie myéloïde aiguë Ceased WO2008073316A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07862659.5A EP2097535B1 (fr) 2006-12-07 2007-12-07 Identification et isolation de cellules souches de leucémie myéloïde aiguë

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87365306P 2006-12-07 2006-12-07
US60/873,653 2006-12-07

Publications (2)

Publication Number Publication Date
WO2008073316A2 WO2008073316A2 (fr) 2008-06-19
WO2008073316A3 true WO2008073316A3 (fr) 2008-10-23

Family

ID=39512275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025113 Ceased WO2008073316A2 (fr) 2006-12-07 2007-12-07 Identification et isolation de cellules souches de leucémie myéloïde aiguë

Country Status (3)

Country Link
US (2) US7767410B2 (fr)
EP (1) EP2097535B1 (fr)
WO (1) WO2008073316A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
WO2008073316A2 (fr) * 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification et isolation de cellules souches de leucémie myéloïde aiguë
ES2796085T3 (es) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Marcadores de células madre de leucemia mieloide aguda
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
CA3138956A1 (fr) 2010-05-14 2011-11-17 The Board Of Trustees Of The Leland Stanford Junior University Anticorps monoclonaux anti-cd47 humanises et chimeres
US20140148351A1 (en) * 2010-09-30 2014-05-29 The Board Of Trustees Of The Leland Stanford Junior University Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature
NZ717534A (en) * 2013-08-22 2022-04-29 Council Queensland Inst Medical Res Immunoreceptor modulation for treating cancer and viral infections
AU2014308552B2 (en) * 2013-08-22 2020-02-13 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
US20160200814A1 (en) * 2013-08-22 2016-07-14 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
IL296410A (en) 2015-11-27 2022-11-01 Cartherics Pty Ltd Genetically modified stem cells and their uses
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
TWI758558B (zh) 2017-11-10 2022-03-21 大陸商江蘇恒瑞醫藥股份有限公司 Cd96抗體、其抗原結合片段及醫藥用途
CN111118099A (zh) * 2018-10-30 2020-05-08 启迪汉洱康（嘉兴）生物科技有限公司 一种用于白血病高通量药物筛查的方法
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
BR112022005787A2 (pt) 2019-09-27 2022-06-21 Glaxosmithkline Ip Dev Ltd Proteínas de ligação a antígeno

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073316A2 (fr) * 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification et isolation de cellules souches de leucémie myéloïde aiguë

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DICK J.E.: "Acute Myeloid Leukemia Stem Cells", ANN. N.Y. ACAD. SCI., vol. 1044, 2005, pages 1 - 5, XP008110524 *
GRAMATZI M. ET AL.: "Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia", EXP. HEMATOLOGY, vol. 26, 1998, pages 1209 - 1214, XP008109027 *
GRIMWADE D. ET AL.: "Acute promyelocytic leukemia: where does it stem from?", LEUKEMIA, vol. 18, 2004, pages 375 - 384, XP008109010 *
HOPE K.J. ET AL.: "Acute myeloid leukemia orginates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity", NATURE IMMUNOLOGY, vol. 5, no. 7, July 2004 (2004-07-01), pages 738 - 743, XP008109008 *
HOSEN N. ET AL.: "CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia", PNAS, vol. 104, no. 26, 26 June 2007 (2007-06-26), pages 11008 - 11013, XP008109009 *
See also references of EP2097535A4 *

Also Published As

Publication number Publication date
US20100255575A1 (en) 2010-10-07
US8232071B2 (en) 2012-07-31
EP2097535B1 (fr) 2016-09-21
WO2008073316A2 (fr) 2008-06-19
US7767410B2 (en) 2010-08-03
EP2097535A4 (fr) 2010-03-03
US20080187950A1 (en) 2008-08-07
EP2097535A2 (fr) 2009-09-09

Similar Documents

Publication Publication Date Title
WO2008073316A3 (fr) Identification et isolation de cellules souches de leucémie myéloïde aiguë
WO2012021795A3 (fr) Biomarqueurs du cancer du pancréas et leurs utilisations
WO2011098262A3 (fr) P19arf, hmga2 et mdm2 destinés à être utilisés dans le diagnostic et le traitement d'une croissance cellulaire aberrante
WO2007079183A3 (fr) Populations de cellules souches placentaires
WO2008063675A3 (fr) Cellules progénitrices endothermiques
WO2009058911A3 (fr) Préparation et isolement d'un arnm coiffé en 5'
EP4470556A3 (fr) Marqueurs de cellules souches de leucémie myéloïde aiguë
WO2006138275A3 (fr) Compositions et procedes de traitement et de diagnostic de cancer
WO2008148105A8 (fr) Cellules souches endométriales et procédés de génération et d'utilisation de celles-ci
GB2449772A (en) Large scale production of stem cells
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
WO2007093657A3 (fr) Procédé destiné au diagnostic moléculaire du cancer de la prostate et nécessaire destiné à mettre en oeuvre ce procédé
WO2008091908A3 (fr) Cellules souches cancéreuses humaines
WO2006135886A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer
WO2007130646A3 (fr) Co-récepteur de vhc et ses méthodes d'utilisation
WO2008094545A3 (fr) Méthodes et compositions à base de micro-arn pour le diagnostic, le pronostic et le traitement de la leucémie aiguë myéloïde (lam)
WO2006083782A3 (fr) Differenciation dirigee de cellules souches embryonnaires et utilisations associees
WO2009048530A3 (fr) Dosages à base de particules hautement multiplexées
SG170065A1 (en) Human embryonic stem cell methods and podxl expression
WO2009114185A3 (fr) Procédés et compositions pour profil translationnel et phénotypage moléculaire
WO2009015359A3 (fr) Sondes spécifiques des chromosomes hautement visibles et procédés associés
AU2019268061A1 (en) Placental stem cell populations
WO2006017150A3 (fr) Identification de marqueurs dans le cancer du poumon et dans le cancer du sein
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2006133923A3 (fr) Diagnostic, pronostic, et prediction de la recurrence des cancers du sein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862659

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007862659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007862659

Country of ref document: EP